Lilly

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Novartis may have been first-to-market with Cosentyx, but it is still facing increasing competition, namely from Eli Lilly’s Taltz (ixekizumab). The rival IL-17 inhibitor won approval in

J&J’s Invokana gets lifeline with new kidney disease approval

Sales have been falling around 20% a year since, coming in at $881m last year, as rival drugs in the class such as Eli Lilly/Boehringer Ingelheim’s Jardiance (empagliflozin) and

Innate Pharma and AstraZeneca take monalizumab into phase 3

The biotech – based in Marseille, France – will proceed into a phase 3 trial evaluating monalizumab in combination with Eli Lilly’s Erbitux (cetuximab) in patients suffering from recurrent or metastatic squamous

NICE delivers final ‘no’ for Novartis’ migraine treatment Aimovig

Since being approved by the European Commission in  2018, Novartis has seen rivals emerge from Eli Lilly (Emgality) and Teva (Ajovy) introduced to the market.

Novo Nordisk gets FDA okay for new diabetes hope

the company’s market share is being squeezed as Lilly’s drug looks set to top the $4bn threshold this year. ... Lilly is also angling for a cardiovascular outcomes claim for Trulicity based on the  REWIND study data, with an FDA decision on that

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]